Frentizole is primarily known for its immunomodulatory properties and has been investigated for use in autoimmune diseases. It was studied as a potential treatment for rheumatoid arthritis due to its ability to suppress abnormal immune responses. The compound works by inhibiting the production of certain pro-inflammatory cytokines and modulating T-cell activity, which helps reduce inflammation and tissue damage. Although it showed promise in preclinical and early clinical trials, development was discontinued due to toxicity concerns. Despite this, frentizole served as a lead compound in the research of thiazole-based immunosuppressants, contributing to the understanding of immune system regulation and the design of safer analogs.